Imatinib mesylate and nilotinib are highly effective at eradicating the majority of chronic myeloid leukemia (CML) cells; however, neither agent induces apoptosis of primitive CML CD34 þ cells. One possible explanation is that CD34 þ cells do not accumulate sufficient intracellular drug levels because of either inadequate active uptake or increased efflux. To determine the interaction of nilotinib with major clinically implicated drug transporters, we analyzed their interactions with MDR1 (ABCB1), MRP1 (ABCC1), ABCG2 (BCRP) and human organic cation transporter (hOCT)1 in CML cell lines and primitive (CD34 þ ) primary CML cells. Nilotinib is neither dependent on active import by hOCT1, nor effluxed through the ATP-binding cassette transporters analyzed. Indeed, we found nilotinib to be an inhibitor of hOCT1, MDR1 and ABCG2. The efflux transporters MDR1, MRP1 and ABCG2 are expressed on CML CD34 þ cells at 13.5, 108 and 291% of control, respectively, although hOCT1 expression was absent; however, inhibition of efflux transporter activity did not potentiate the effect of nilotinib on apoptosis, Bcr-Abl inhibition or CML CD34 þ cell proliferation. Therefore, we have found no evidence for either active uptake of nilotinib through hOCT1 or efflux through MDR1, MRP1 or ABCG2, and it is therefore unlikely that these transporters will have any effect on the clinical response to this drug.
Introduction
In response to resistance and failure to induce molecular responses in a proportion of chronic myeloid leukemia (CML) patients treated with imatinib (Gleevec; Glivec; Novartis, Basel, Switzerland), 1,2 new tyrosine kinase inhibitors (TKIs) have been developed and both nilotinib (Tasigna; Novartis) and dasatinib (Sprycel; Bristol-Myers Squibb, Stamford, CT, USA) are now in clinical use. 3, 4 Despite the improved potency (20-fold) of nilotinib in cell lines and on bulk primary CML cells, we have found that nilotinib is no more effective than imatinib in inducing apoptosis of primitive CD34 þ CML cells. 5 Furthermore, we have shown that as with imatinib, CD34
þ CML cells persist after treatment and that nilotinib is anti-proliferative rather than proapoptotic, resulting in the accumulation of quiescent CD34 þ cells. 5 We, along with others, have suggested that this population of primitive cells that are insensitive to imatinib and nilotinib may form a pool of disease in patients under treatment and contribute to the Bcr-Abl molecular signal detected in the majority of patients. 6, 7 This population, therefore, must be specifically targeted in order to cure rather than control the disease in patients.
One possible reason for the failure of nilotinib to kill CD34 þ primitive CML cells is the insufficient intracellular levels of the drug owing to inadequate active uptake through the solute carrier transporter family, or because of efflux through multidrug resistance proteins of the ATP-binding cassette family. There has been much debate about the role of ATP-binding cassette transporters in mediating imatinib resistance; these include our own investigations into ABCG2 activity in CML CD34 þ cells. 8 Imatinib may be an inhibitor or substrate of ABCG2 depending on its concentration, [9] [10] [11] but in CD34 þ cells, at concentrations above clinical trough plasma values (1.2 mM), it is an inhibitor. 8 Imatinib may also be a substrate for MDR1 (ABCB1, P-gp) in cell lines;
12-14 however, we have not found this in primary CML cells. 15 Furthermore, a number of studies including our own have shown that imatinib is actively taken up through the human organic cation transporter 1 (hOCT1; solute carrier 22a1), [12] [13] [14] [15] [16] [17] and that reduced hOCT1 expression may correlate with a poor clinical response. 17 To date there have been only two reports suggesting that nilotinib may be an ABCG2 substrate but is not actively taken up by hOCT1. 18, 19 We have now analyzed the interaction of nilotinib with the major clinically implicated drug transporters MDR1, MRP1 (ABCC1), ABCG2 and hOCT1 in CML cell lines and primary CD34 þ cells. In addition, we have co-treated these primitive cells with nilotinib in the presence of efflux transporter inhibitors to analyze whether this renders the drug more effective.
Materials and methods

Reagents
14 C-labelled imatinib (specific activity, 3.386 MBq/mg), nilotinib (specific activity, 3.480 MBq/mg) and the MDR1 inhibitor PSC833 were kindly provided by Novartis. 14 C-labelled tetraethylammonium bromide (TEA) (specific activity, 118.4 MBq/ mmol) was purchased from Perkin-Elmer Life Sciences (Boston, MA, USA) and Gold Star scintillation cocktail from Meridian (Epsom, UK).
Cell culture
Transfection of KCL22 cells with hOCT1 was performed as described earlier. 20 The MDR1-transfected Type II Marin Darby canine kidney (MDCKII) cell line was a kind gift from Professor P Borst (Netherlands Cancer Institute). 16 
Cellular analysis
Intracellular phospho-CrkL (p-CrkL), annexin V/propidium iodide and carboxyfluorescein succinimidyl ester stainings were conducted and analyzed by flow cytometry as described earlier. 22, 23 Cell viability and counts were determined by dye exclusion.
Efflux studies
The efflux protocol was a modification that described earlier. 24 Cells were incubated with appropriate concentrations of inhibitors/TKI as required for 15 min to block pump activity before the incubation with fluorescent substrates for a further 30 min. Cells were washed and incubated with or without inhibitors/TKI for 1 h to allow efflux before washing in ice-cold medium for analysis. 8 The fluorescent substrates and inhibitors used were Rhodamine-123 (0.5 mg/ml; Invitrogen, Paisley, UK) and PSC833 (5 mM) for MDR1; Fluo3-AM (5 mg/ml; Axxora, Nottingham, UK) and MK571 (30 mM; Axxora) for MRP1; and BODIPY-Prazosin (200 nM; Axxora ) and fumitremorgin C (FTC, 10 mM; Axxora) for ABCG2. Retention values were calculated by designating the level of fluorescence in the presence of the known inhibitor as 100%.
Radio-labelled intracellular uptake and retention assay using KCL22 cells Drug transport studies of 14 C-radio-labelled nilotinib (4 and 1 mM, spanning peak and trough plasma levels, respectively, of a 400-mg twice daily dose) were performed using high expressing hOCT1-transfected KCL22 cells, with or without hOCT1 and MDR1 inhibitors/substrates. MDR1 inhibitors used were PSC833 (10 mM), verapamil (500 mM) and tariquidar (500 nM). OCT1 inhibitors/substrates used were prazosin (100 mM), amantadine (500 mM) and TEA (5 mM). After drug treatment, cells were lysed before scintillation counting as published earlier. 16 Cellassociated nilotinib levels were expressed as ng per million cells.
Measurement of transepithelial drug transport by MDR1
Vectorial MDR1 efflux studies were conducted on MDCKII cells as described earlier. 16 Cells were seeded at 1.5-2 Â 10 6 cells per well onto 24-mm diameter, 0.4-mm pore size, polycarbonate transwell membrane inserts (Appleton Woods, UK). After 5 to 6 days, transepithelial electrical resistance was measured, using a Millicell-ERS Volt-ohmmeter (Millipore, UK) to determine a confluent monolayer. The blank membrane resistance was subtracted from monolayer resistance, then multiplied by the surface area (4 C-imatinib (5 mM) or 14 C-nilotinib (4 mM) for 4 h. Radioactivity was measured in medium from donor and acceptor compartments by liquid scintillation spectrometry. TKI movement was calculated as a percentage of the radioactivity transported across the monolayer. 25 For MDR1 inhibition studies MDCKII-MDR1 cells were pre-incubated with PSC833 (10 mM) 30 min before the addition of the radioactive TKIs, as described above.
Distribution coefficient (log D)/lipophilicity studies
The lipophilicity of a compound is defined as the distribution coefficient (log D) in a biphasic system. The log D values of 14 C-labelled nilotinib and imatinib were measured as described by Yunger and Cramer. 26 In brief, equimolar quantities of the drugs (500 nM) were suspended in 1-ml transport medium, and then mixed vigorously for 15 min with 1-ml 1-octanol. The layers were separated by centrifugation at 2000 r.p.m. for 10 min at room temperature. Radioactivity was determined by scintillation counting of 500 ml aliquots from both phases. Results were derived from three experiments, each consisting of four replicates. The log D distribution coefficient was calculated as below, in which DPM represents disintegrations per minute:
Results and discussion
There has been much debate about the most suitable imatinib or nilotinib concentration for in vitro study that most closely represents clinically achievable levels. In our recent preliminary work, 27 we have shown that plasma levels of 2.7 mg/ml are achieved 10 h after administering 400 mg imatinib; those taking 600-800 mg achieved imatinib plasma levels above 3 mg/ml 10-16 h after the dose. Therefore, an imatinib plasma level of 5 mM (2.95 mg/ml) is clinically achievable. Similarly, the use of 1 and 4 mM nilotinib spans the upper and lower standard deviation range of serum steady-state C max levels for the typical 800 mg daily dose (Novartis: data on file via personal communication with Dr P Manley, Novartis Pharma, 2008), which is supported by plasma-level data generated from patient pharmacokinetic profiles at the Royal Liverpool University Hospital. On the basis of these data, we consider that our use of these concentrations of TKI more closely mimics in vivo conditions than the use of low submicromolar concentrations as in some other transport studies.
Nilotinib is more lipophilic than imatinib and cellular accumulation is not dependent on active import by human organic cation transporter 1
We, along with others, have shown that the response to imatinib both in vitro and in vivo is dependent on active uptake into the cells via the solute transporter hOCT1. 16, 19, 28 However, little is known about the mechanism by which nilotinib enters the cells. In the only earlier study by White et al., 19 unlike the effect on imatinib transport, inhibition of hOCT1 activity by prazosin did not decrease nilotinib uptake into CML cells. Our data, using a stably transfected cell line model, extend this earlier investigation and strongly support that hOCT1 is not involved in the import of nilotinib (Figure 1a and b). We have also shown that nilotinib uptake was not temperature dependent and occurred very rapidly, reaching maximal levels by the first time point of 2 min (Figure 1a) , which is consistent with our finding that nilotinib was more lipophilic than imatinib as measured by calculation of log D (2.4 vs 0.8, respectively) and, therefore, is more likely to be taken up into the cells without active transport.
The passive nature of this uptake is also shown by the data in Figure 1a , and it also shows that nilotinib levels are unaffected by the level of expression of hOCT1. KCL22 cells transfected with hOCT1 were also exposed to nilotinib in the presence of hOCT1 and two-inhibitor amantadine, or hOCT1 and threeinhibitor prazosin, neither of which altered the uptake of nilotinib (Figure 1b) . The efficient 1-h uptake of nilotinib in the absence of hOCT1 transport was confirmed at a functional level by measuring reduction in Bcr-Abl activity using p-CrkL as a surrogate marker (data not shown). Nilotinib reproducibly 
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reduced CrkL phosphorylation to a greater extent than imatinib, but, in contrast to imatinib treatment, p-CrkL levels were not altered by the over-expression of hOCT1 in KCL22 cells (imatinib-treated pcDNA 78.6±12.6% vs hOCT1 39.8±5.8%; P ¼ 0.0185; nilotinib-treated pcDNA 37.4 ± 8.0% vs hOCT 49.4±14.1%; P ¼ 0.477: n ¼ 6, ±s.e.m.).
Interestingly, our studies show that nilotinib can reduce uptake of TEA, a known hOCT1 substrate, suggesting that nilotinib disrupts hOCT1 transport function (Figure 1c) . We have also observed such activity for imatinib; however, nilotinib was more potent than imatinib in this regard. In isolation these data may suggest that nilotinib reduces TEA uptake as a competitive substrate; however, as we did not observe any evidence that nilotinib is a substrate for hOCT1 (Figures 1a and b) , we consider that nilotinib impedes TEA uptake by inhibiting the function of the transporter. Therefore, drugs transported by hOCT1 would be blocked when co-administered with nilotinib. This is further supported by our observation that nilotinib, at 1 and 4 mM, abolished 14 C-imatinib uptake in KCL22-hOCT1 cells (data not shown); similar data have been reported by White et al. 28 Given the ability of nilotinib to inhibit hOCT1, one must consider the possibility of drug-drug interactions. For instance, the anti-diabetic agent metformin is a substrate for hOCT1 transport; 20 and therefore co-administration with nilotinib may inhibit metformin uptake, which may have a clinically relevant impact on the control of glucose levels in diabetic CML patients taking nilotinib.
On the basis of the findings from this study, we conclude that nilotinib enters cells passively and can accumulate readily. Hence, unlike imatinib, modulating the uptake of which may help improve the performance of the drug, it is unlikely that the intracellular concentration of nilotinib can be further increased by solute carrier modulation.
Nilotinib is not effluxed by clinically relevant drug transporters
In addition to examining the drug uptake, there have been a number of contradictory studies analyzing whether efflux transporters may limit the intracellular concentration and thus the efficacy of imatinib. [8] [9] [10] [11] [12] [13] [14] [15] [16] 29 To date the transporter that has been studied in most detail is ABCG2. There is still no consensus on whether imatinib is a substrate or inhibitor of this protein; however, collation of all the data supports the proposal of a dual activity, whereby at low concentration (p0.8 mM) imatinib is a substrate and at higher concentrations it is an inhibitor of ABCG2. [9] [10] [11] Our own studies have shown that ABCG2 is over-expressed on CML CD34 þ cells, but that inhibition of efflux does not increase the effect of imatinib in this population containing the CML stem cells. 8 There have been few comprehensive studies on the interaction between imatinib and MDR1 cells in primary CML stem cells, but cell line studies suggest it may be an MDR1 substrate. 13, 14, 29 Our most recent work in primary CML CD34 þ cells suggests (1) that MDR1 is expressed at very low levels in these cells, and (2) that as the interaction of imatinib with MDR1 is as an inhibitor, transporter blockade is unlikely to be significant in this population. 15 We found that nilotinib was not a substrate for any of the transporters tested in cell line models. In a vectorial transport assay, on the basis of MDCKII cells engineered to over-express MDR1 apically, whereby basal-to-apical exceeds the apical-tobasal transport of MDR1 substrates, the transport of 14 C-nilotinib across the monolayer in either direction was decreased compared with imatinib ( Figure 1d ) and was not altered by the MDR1 inhibitor PSC833. This lack of efflux by MDR1 was confirmed by the uptake and retention of nilotinib into KCL22 cells being unaffected by the MDR1 inhibitors verapamil, PSC833 or tariquidar (Figure 1e) . We also used cell lines expressing various transporters in 14 C-nilotinib uptake assays (Supplementary Figure 1 , upper panels) and in fluorescent substrate assays (Supplementary Figure 1, lower panels) . Expression of MDR1, MRP1 or ABCG2 did not decrease the retention of 14 C-nilotinib; furthermore, inhibition of these efflux transporters with the specific inhibitors PSC833, MK571 or FTC did not cause any increase in drug retention (Supplementary Figure 1,  upper panels) . However, in substrate efflux assays (Supplementary Figure 1 , lower panels) nilotinib significantly reduced the efflux through MDR1 or ABCG2 and had a small inhibitory effect on MRP1-mediated efflux. Therefore, although nilotinib is not a substrate for any of these transporters, it can inhibit the efflux through MDR1 or ABCG2.
To analyze whether the poor response of CML CD34 þ cells to nilotinib was because of low intracellular accumulation, we looked at the expression of messenger RNA using quantitative polymerase chain reaction for the three main clinically relevant transporters MDR1, MRP1 and ABCG2, which have earlier been associated with drug resistance in leukemia. 30, 31 We found that all three efflux transporters are expressed in CD34 þ CML cells; however, hOCT1 was below the level of detection in normal or CML CD34 þ cells. MRP1 was detected at levels similar to those in normal CD34 þ cells (108%), ABCG2 at higher levels (291%) as reported earlier 8 and, surprisingly, MDR1 was found to be expressed at a lower level in CML (13.5%) than in normal CD34 þ cells (Supplementary Table 1 ). MDR1 expression is often elevated in leukemia and indeed has been found at higher levels in CML versus normal mononuclear cells and in primary cells from patients with advanced-phase CML; 32 however, this is not the case in the more primitive population in chronic phase, underlining the key differences depending on cell type and disease phase.
As all the three efflux transporters were expressed, we assessed the interaction of nilotinib in primary CML CD34 þ cells and tested the effect of inhibiting the transporters while these cells were treated with nilotinib. As shown in the upper and middle panels of Figure 2 , CML CD34 þ cells showed moderate substrate efflux through MDR1 (56.2±11.5% retention) and ABCG2 (54.4 ± 19.3% retention), but a very high level of MRP1 activity (4.89±0.22% retention). These levels of activity correlate with the relative levels of messenger RNA for these transporters (Supplementary Table 1 ). When the known inhibitors were replaced with increasing doses of nilotinib (Figure 2 , lower panel) the TKI had no significant effect on MDR1 activity (70.6 ± 9.8% retention at 5 mM); however, it was difficult to determine the reproducibility because of the low control level of MDR1-mediated efflux. Similarly, efflux of BODIPY-prazosin through ABCG2 was not seen to any significant degree within this cohort of samples; the expression level of ABCG2 was also lower than that reported for an earlier cohort. 8 We were therefore unable to confirm the inhibitory effect seen with nilotinib in ABCG2 over-expressing cell lines and in CML CD34 þ cells. However, CML CD34 þ cells showed a high degree of efflux of Fluo3-AM via MRP1 (4.89 ± 0.22% retention), and this efflux was slightly reduced by nilotinib (15.3 ± 6.0% retention at 5 mM vs 4.89 ± 0.22% with control; not statistically significant). In addition, CD34
þ CML cells were incubated in nilotinib with and without the individual inhibitors to directly assess the effect of transporter inhibition on the intracellular concentration by high-pressure liquid chromatography analysis. The individual inhibitors had no effect on this concentration, nor did the combined use of all three inhibitors (data not shown). Therefore, as seen in the cell lines, although nilotinib may have some inhibitory effect on MDR1 and ABCG2 (and hOCT1), it is not a substrate for these transporters and the intracellular concentration of this TKI is not controlled by any of the transporters tested.
These findings are somewhat different from those of Mahon et al., 33 who have reported that nilotinib-resistant cell lines have elevated MDR1 expression. However, those studies made use of the cell lines that had developed resistance after prolonged exposure to nilotinib rather than by over-expression of specific transporters. This might be the reason why it was not possible to fully differentiate between MDR1-mediated effects and other mechanisms of resistance such as Bcr-Abl over-expression or lyn activity. In addition, unlike the earlier study, we have directly measured drug accumulation in addition to cell death and MDR1 inhibitor effects, and our finding that nilotinib is not a substrate for MDR1 is in agreement with the earlier report of White et al., 28 who found that inhibition of MDR1 in mononuclear cells from chronic-phase CML patients did not increase the intracellular concentration of nilotinib, nor did MDR1 expression protect the cell lines from nilotinib-induced death.
Another earlier study suggested that nilotinib is transported by ABCG2 at low concentrations, 18 but the study was conducted on cell lines and normal stem cells. Furthermore, the concentrations at which nilotinib was transported were in the low nanomolar range, and were far below even trough levels measured in patient serum. We have used seemingly high concentrations of nilotinib throughout these experiments primarily because we have earlier seen that even these concentrations do not kill CD34 þ cells, and it is this insensitivity in the stem cell population that we specifically wish to analyze. In addition, the doses we used (1-5 mM) are similar to the observed peak values of 3.6 mM achieved by standard 400 mg twice daily dosing. However, CML stem cells may reside within bone marrow niches and therefore may not be exposed to serum concentrations of drug. It is not practical to measure the amount of drug within specific niches, but we have found earlier that there is no significant difference in the concentration of imatinib found in bone marrow extracts and peripheral blood samples (Jorgensen and Holyoake, unpublished data). We have not made these measurements for nilotinib, but, given the similar pharmacokinetic data for nilotinib and imatinib, we suggest that the distribution of nilotinib would not be significantly lower in bone marrow than blood, but we cannot exclude the possibility of highly localized depletion in the defined stem cell niche. Our finding that nilotinib is not a substrate for MDR1 is in agreement with the earlier report of White et al., 28 who found that Transporter activity does not modulate the effect of nilotinib on primary chronic myeloid leukemia CD34 þ cells
The proposal that drug transport is not responsible for the insensitivity of CD34 þ cells to nilotinib is further supported by our findings from co-treatment experiments. Blockade of ABCG2 or MRP1, with FTC or MK571, respectively, did not potentiate the effect of nilotinib on CD34
þ CML cells over a period of 72-h treatment ( Figure 3 ). P-CrkL assays at 72 h showed that nilotinib significantly reduced the activity of Bcr-Abl in these cells (62.2 ± 12.21% at 72 h) compared with control, but this reduction was not potentiated by inhibition of efflux transporters (Figure 3a) . Similarly, when the total number of cells remaining in the cultures was assessed at 72 h (Figure 3b ), nilotinib treatment resulted in reduced cell numbers because of both anti-proliferative and pro-apoptotic effects as expected. Neither MRP1 nor ABCG2 inhibition further decreased the cell numbers. However, the effect of MDR1 inhibition with PSC833 was less clear.
PSC833 has earlier been found to have unacceptable toxicity in vivo, 34 resulting in early termination of trials using this agent. Our preliminary experiments showed that the standard concentration of 10mM used for cell line studies caused significant apoptosis and was profoundly cytostatic in CML CD34 þ cells (data not shown). Therefore, we reduced the concentration to 5 mM, which still gave full inhibition of Rhodamine-123 efflux in cell lines but had a less detrimental effect on CD34 þ cells. However, we still saw an increase in cell death and some antiproliferative effect when the CML CD34 þ cells were treated with PSC833 alone; this effect was maintained in the presence of nilotinib and therefore the combination resulted in a further reduction in the number of cells remaining in culture. Although this result initially seems to show that MDR1 inhibition enhances the effect of nilotinib, we did not see an additive effect on the reduction of Bcr-Abl activity by the p-CrkL assay, nor did we measure any increase in the intracellular concentration of nilotinib by radio-labelled or high-pressure liquid chromatography analyses. We therefore conclude that the effect of PSC833 is not associated with the transport of nilotinib.
The data may indicate that there is an endogenous substrate that accumulates when MDR1 is inhibited and that is toxic to the cells, or simply that PSC833 has a nonspecific toxic effectFwe consider the latter to be most likely. In support of this, Mahon et al. 29 also reported unexpected results when using PSC833 with CML cells. We also suggest that this nonspecific effect may underlie some of the confusion regarding the effect of 
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A Davies et al MDR1 inhibition in earlier cell line studies of imatinib. In such studies, PSC833 appeared to increase the response to nilotinib and imatinib; however, detailed analyses, such as determination of drug accumulation and activity, are required to deconvolute this effect and have not been performed in many of these studies. Finally, we looked at the number of CD34 þ cells that remained quiescent in culture during the treatment ( Figure 3c) ; this population represents the putative CML stem cell population that is resistant to TKI and may be responsible for clinical persistence of the disease. As we have reported earlier, nilotinib increased the number of these cells ( Figure 3c) ; however, there was no significant effect on this population in response to transporter inhibition alone or in combination with nilotinib.
In conclusion, we have found no evidence for either active uptake of nilotinib through hOCT1 or efflux through MDR1, MRP1 or ABCG2. It is therefore unlikely that differential expression or function of these transporters will have any effect on the clinical response to this drug in either mononuclear cells or the more resistant CD34
þ stem cell population. However, nilotinib seems to be an inhibitor of both influx and efflux pumps, and is therefore liable to be involved in drug-drug interactions.
